Back to search results

IGNITE-TX Intervention for Genetic Testing and Counseling

This study, called IGNITE-TX, is looking at a program designed to help people with certain genetic changes (like in BRCA1 or BRCA2) talk with their family members about genetic testing and make informed decisions. The program, called IGNITE-TX, will be compared to standard care, free genetic testing and counseling, or a combination of the IGNITE-TX program with free genetic testing and counseling. You might be able to join if you are 18 or older, live in the US, speak English or Spanish, and have a specific genetic change in genes like BRCA1 or BRCA2. The main goal is to see how well the IGNITE-TX program helps family members get genetic testing and improves family communication and support. The study's current status is unclear.

Study design
This is an interventional study with a planned enrollment of 2100 participants. It compares different approaches to genetic counseling and testing.
What's involved
Participants will complete questionnaires as part of the IGNITE-TX program or genetic counseling and testing. The study will last for an average of one year.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of one year. The impact of the intervention will be evaluated at 6 and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07318363

IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention

Not Yet Recruiting
PHASE3Ages 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~2,100 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:IGNITE-TX programGenetic Counseling and Testing

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Communication
Informed Decision-making

Explore related trials

Informed Decision-makingNo communicationBRCA1 GeneBRCA2 GeneDNA Mismatch Repair Protein Mlh1EPCAM GeneMSH2 GeneMSH6 GenePMS2 GeneRAS Family Protein VariantSandhoff Disease

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Jose Alejandro Rauh-Hain, MD, MPH · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Jose Alejandro Rauh-Hain, MD, MPH
[email protected]
(713) 794-1759
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

For cancer patients who are unaware of their mutation status, we will share existing local and national genetics resources, like those provided in the usual care family letter.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0